Rising diagnosis rates and expanded access to orphan disease therapies increase demand for primary biliary cholangitis treatment across the Middle East

The Middle-East Primary Biliary Cholangitis Therapeutics market is expected to grow from USD 250.0 Million in 2024 to USD 550.0 Million by 2034, reflecting steady demand for therapies used to manage chronic autoimmune liver disease. Growth is supported by improving diagnosis of rare liver disorders and expanding access to specialty healthcare services across Gulf Cooperation Council (GCC) countries. Governments in the region continue to invest in tertiary care hospitals and rare disease treatment programs as part of broader healthcare modernization strategies. The World Health Organization (WHO) has also highlighted the importance of strengthening early diagnosis and management of chronic liver diseases, while national health authorities across the Middle East are expanding specialist hepatology services and improving access to orphan medicines.

Request Free Sample: https://www.emergenresearch.com/request-sample/219181

KEY GROWTH DRIVERS

Increasing awareness among healthcare professionals, wider availability of diagnostic testing, and the adoption of guideline-based treatment protocols are supporting demand for primary biliary cholangitis therapeutics. The market is also benefiting from higher healthcare expenditure across the Middle East and growing investments in specialty pharmaceutical distribution networks. Pharmaceutical companies continue to pursue regulatory approvals and commercial partnerships for therapies targeting rare liver diseases. For instance, in August 2024, Ipsen, France, announced the completion of its acquisition of Albireo, strengthening its portfolio in rare hepatology diseases and expanding its presence in cholestatic liver disorders. Healthcare reforms across countries including Saudi Arabia and the United Arab Emirates are also improving patient access to advanced therapies through public reimbursement and specialized treatment centers. These are some of the key factors driving revenue growth of the Middle-East Primary Biliary Cholangitis Therapeutics market.

MARKET RESTRAINTS

However, the market continues to face several challenges. Primary biliary cholangitis remains a rare disease, resulting in delayed diagnosis and limited patient awareness across several Middle Eastern countries. The high cost of second-line therapies and biologic medicines creates affordability concerns, particularly in countries with limited reimbursement coverage. Regulatory approval timelines for orphan drugs and unequal access to specialist hepatology care outside major urban centers also affect treatment availability. These factors are expected to limit Middle-East Primary Biliary Cholangitis Therapeutics market growth to some extent over the forecast period.

Request Customization: https://www.emergenresearch.com/request-for-customization/219181

SEGMENT HIGHLIGHTS

The ursodeoxycholic acid (UDCA) segment accounted for the largest share of the market in 2024. UDCA remains the standard first-line treatment for primary biliary cholangitis and is recommended in international clinical practice guidelines because of its established safety profile and long-term clinical evidence. Its broad availability across hospitals and specialty pharmacies continues to support its leading position.

The obeticholic acid segment is expected to record the fastest growth during the forecast period. The therapy is increasingly prescribed for patients who do not achieve an adequate response to UDCA or cannot tolerate first-line treatment. Continued clinical research and wider regulatory acceptance of second-line therapies are expected to support adoption across specialized liver care centers.

Buy Full Report: https://www.emergenresearch.com/select-license/219181

REGIONAL OUTLOOK

North America continues to account for a large share of the global primary biliary cholangitis therapeutics market due to established healthcare infrastructure, early diagnosis, and the presence of major pharmaceutical companies. The U.S. Food and Drug Administration (FDA) continues to support orphan drug development through regulatory incentives, encouraging innovation in therapies for rare liver diseases. Companies including Gilead Sciences and Mirum Pharmaceuticals continue to expand clinical research activities in hepatology.

Europe maintains steady market growth through comprehensive rare disease policies and broad reimbursement systems. The European Medicines Agency (EMA) supports the development and review of orphan medicines, while countries including Germany, France, and Italy continue to invest in specialized liver disease treatment centers. Companies such as Ipsen are expanding their rare disease portfolios through acquisitions and product development.

Asia Pacific is expected to register the fastest growth over the forecast period due to expanding healthcare infrastructure, rising awareness of autoimmune liver diseases, and improving access to specialty medicines. Governments in countries such as China, Japan, and South Korea continue to strengthen rare disease diagnosis and treatment programs. Regional pharmaceutical manufacturers are also increasing investments in specialty therapeutics through licensing agreements and research collaborations.

Middle-East Primary Biliary Cholangitis Therapeutics Market Segmentation Analysis

Product Type Outlook (Revenue, USD Million, 2024 - 2034)
Pharmacological Therapies
Supportive Therapies

Application Outlook (Revenue, USD Million, 2024 - 2034)
Hospitals
Clinics
Homecare Settings

End-Use Outlook (Revenue, USD Million, 2024 - 2034)
Healthcare Providers
Pharmaceutical Companies
Research Institutions

Regional Outlook (Revenue, USD Million, 2024 - 2034)
Middle East
Saudi Arabia
United Arab Emirates
Qatar
Kuwait
Others

MEDIA CONTACT
Contact us:
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +12092086299
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

ABOUT EMERGEN RESEARCH
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.